title: Frequency and characteristics of docetaxel-induced radiation recall phenomenon.
abstract: OBJECTIVE
  The aim of this study was to investigate the frequency and characteristics of a docetaxel-induced radiation recall phenomenon.
  
  
  METHODS
  Past histories of radiotherapy and radiation recall phenomenon (RRP) were analyzed in 461 patients who were administered docetaxel at our hospital between September 2002 and November 2005.
  
  
  RESULTS
  Of the 461 patients, 171 underwent radiotherapy before starting docetaxel. RRP was noted in 3 patients (1.8%). The 3 cases show that RRP tends to develop in patients treated with lower-energy photon beams of < or =6 MV and in patients with marked acute phase reactions during radiotherapy.
  
  
  CONCLUSIONS
  The incidence of RRP induced by docetaxel was 1.8%, making it a comparatively rare condition. However, docetaxel is increasingly being used for patients with head and neck tumors, and caution regarding development of RRP is warranted after use of docetaxel after high-dose radiotherapy with photon beams of < or =6 MV.
authors.affiliation: Division of Radiation Oncology, Shizuoka Cancer Center Hospital, Nagaizumi, Shizuoka, Japan. mizumoto1717@hotmail.com
authors.forename: Masashi
authors.initials: M
authors.lastname: Mizumoto
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Harada
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Asakura
authors.forename: Sadamoto
authors.initials: S
authors.lastname: Zenda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Fuji
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Murayama
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Nishimura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage; D015897:Comorbidity; D000077143:Docetaxel; D005260:Female; D006801:Humans; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000453:epidemiology*; D011836:Radiation Tolerance / Q000187:drug effects*; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D043823:Taxoids / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel